• Pila Pharma initiated its first clinical site for PP-CT04, enabling enrollment to start in Part 1 of a 12-week obesity trial.
• No trial results have been presented; Part 1 will generate initial safety findings before Part 2 can begin.
• The study tests XEN-D0501, an oral TRPV1 antagonist, aiming to support further development in obesity and diabetes.
• Part 1 enrolls 8 participants with intensified safety monitoring, shaping the decision to expand into the larger second stage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pila Pharma AB published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.